

Ref: FOIA Reference 2018/19-536

Royal Stoke University Hospital
Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 11th January 2019

Tel: 01782 676474
Email FOI@uhn.nhs.uk

Dear

I am writing in response to your email dated 5th December 2018 requesting information under the Freedom of Information Act (2000) regarding metastatic breast cancer. I apologise for the delay in responding.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Within your health Trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.

A1 There were twenty five breast cancer patients who received treatment for distant recurrence of cancer (metastatic disease) during the period 1st April 2018 to 30th September 2018.

Q2 Within your health Trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- disodium pamidronate (Aredia)
- ibandronic acid or ibandronate (Bondronat)
- sodium clodronate (Bonefos, Clasteon, Loron)
- zoledronic acid or zoledronate (Zometa)
- denosumab (Xgeva)

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = less than 5
- sodium clodronate (Bonefos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = less than 5
- denosumab (Xgeva) - 77

Q3 Within your health Trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonafos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**

A3 Please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonafos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = 104

Q4 Within your health Trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care

A4 Fourteen lung cancer patients received treatment for distant recurrence of cancer (metastatic disease) during the period 1st April 2018 to 30th September 2018

Q5 Within your health Trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonafos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A5 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonafos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = less than 5
- denosumab (Xgeva) - 31

Q6 Within your health Trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

A6 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the number as being less than 5.

Q7 Within your health Trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonafos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A7 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers. Please see below.

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonafos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = 0
- denosumab (Xgeva) = less than 5

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Leah Carlisle
Deputy Head of Quality, Safety & Compliance